Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL26599945 | 0.98 | GNAI3 (0.43) | ALOX15GNAI3GNAO1GNAI1TSHR | |
| SCHEMBL321293 | 0.88 | GABRA5 (0.41) | ALOX15GNAI3GNAO1GNAI1TSHR | |
| SCHEMBL1348800 | 0.88 | GABRA5 (0.41) | ALOX15GNAI3GNAO1GNAI1TSHR | |
| SCHEMBL10059949 | 0.88 | GABRA5 (0.41) | ALOX15GNAI3GNAO1GNAI1TSHR | |
| Trifluoroacetic Acid SCHEMBL3529301 | 0.85 | ALOX15 (0.40) | ALOX15GNAI3GNAO1GNAI1TSHR | |
| SCHEMBL2841819 | 0.84 | — | — | |
| SCHEMBL8391559 | 0.80 | ADH1B (0.41) | EPHX1NPY5RADRA2AJAK2JAK1 | |
| SCHEMBL5783979 | 0.80 | ADH1B (0.41) | EPHX1NPY5RADRA2AJAK2JAK1 | |
| SCHEMBL7354566 | 0.80 | LMNA (0.38) | ALOX15GNAI3GNAO1GNAI1TSHR | |
| Hydrochloric Acid SCHEMBL29160768 | 0.80 | GNAI3 (0.46) | ALOX15GNAI3GNAO1GNAI1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| WO-2020210662-A1 | SMALL MOLECULES FOR CANCER THERAPY THAT REDUCE THE EXPRESSION OF TRANSCRIPTION FACTORS KLF5 AND EGR-1 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-2201002-B1 | 5-HT7 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2201002-B1 | 5-HT7 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7910588-B2 | 5-HT7 receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910588-B2 | 5-HT7 receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910588-B2 | 5-HT7 receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-08-05 | — | — | US | disclosed |
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-08-05 | — | — | US | disclosed |
| EP-2201002-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7645774-B2 | Cannabinoid receptor ligands | SCHERING CORPORATION (US) | 2010-01-12 | — | — | US | disclosed |
| WO-2009048765-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009048765-A1 | 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-04-16 | — | — | WO | disclosed |
| CN-1058262-C | Novel 1-phenylalkanone 5-HT4Receptor ligands | SYNTEX INC (US) | 2000-11-08 | — | — | CN | disclosed |
| EP-0700383-B1 | NOVEL 1-PHENYLALKANONE 5-HT 4? RECEPTOR LIGANDS | SYNTEX INC (US) | 1998-09-23 | — | — | EP | disclosed |
| US-5763458-A | NERVOUS SYSTEM DISORDERS, ANXIETY, ANTIDEPRESSANTS AND COGNITION ACTIVATORS | SYNTEX (U.S.A.) INC. (US) | 1998-06-09 | — | — | US | disclosed |
| CN-1124485-A | Novel 1-phenylalkanone 5-HT4Receptor ligands | SYNTEX A INC (US) | 1996-06-12 | — | — | CN | disclosed |
| EP-0700383-A1 | NOVEL 1-PHENYLALKANONE 5-HT 4? RECEPTOR LIGANDS | SYNTEX (U.S.A.) INC. (US) | 1996-03-13 | — | — | EP | disclosed |
| WO-1994027965-A1 | NOVEL 1-PHENYLALKANONE 5-HT4 RECEPTOR LIGANDS | SYNTEX (U.S.A.) INC. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197700-A1 | 5-HT7 RECEPTOR ANTAGONISTS | HTR7, HTR1A, HTR2C | ALOX15 1176/4885GNAI3 626/4885GNAO1 355/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | ALOX15 87/4885GNAI3 1276/4885GNAO1 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.